Highlights Newsletter 4
This newsletter presents you the following key sessions:
1. Video-interview with Alok Khorana, MD, PhD, who presents the latest results of the CASSINI trial regarding
rivaroxaban thromboprophylaxis in high-risk ambulatory cancer patients receiving systemic therapy
2. Superior clinical outcomes with ibrutinib-obinutuzumab compared to chlorambucil-obinutuzumab in the
first-line treatment of chronic lymphocytic leukemia
3. Four cycles of R-CHOP is as effective as six cycles in young patients with favorable-risk diffuse large
B-cell lymphoma
4. Adding daratumumab to lenalidomide-dexamethasone significantly delays disease progression and
increases the response rate in patients with transplant-ineligible newly diagnosed multiple myeloma
5. Luspatercept reduces the need for blood transfusions in anemic patients with myelodysplastic syndromes
who require regular red blood cell transfusions